Rachelle Jacques
Equibles does not estimate personal net worth.
About Rachelle Jacques
Earlier roles on record: CEO at Akari Therapeutics Plc (AKTX) until May 1, 2024. Akari Therapeutics Plc reported in an 8-K filed May 7, 2024 that Rachelle Jacques resigned as Board of Directors, effective May 7, 2024. Akari Therapeutics Plc reported in an 8-K filed May 1, 2024 that Rachelle Jacques resigned as President and Chief Executive Officer, effective May 1, 2024. The proxy statement of Akari Therapeutics Plc reports total compensation of $1,401,173 for Rachelle Jacques in fiscal 2024, including a base salary of $207,582. Disclosed compensation is on record for 3 fiscal years.
“On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the "Board"), effective May 7, 2024.”
“Pursuant to notice provided on April 25, 2024, Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.”
Affiliation history
-
Start not stated–2024-05-01
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Akari Therapeutics Plc (AKTX) | Former President and Chief Executive Officer | $207,582 | $1,401,173 |
| 2023 | Akari Therapeutics Plc (AKTX) | Former President and Chief Executive Officer | $615,750 | $1,560,141 |
| 2022 | Akari Therapeutics Plc (AKTX) | Former President and Chief Executive Officer | $458,333 | $3,602,599 |